Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 35

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Pharmacological stimulation of p53 with low-dose doxorubicin ameliorates diet-induced nonalcoholic steatosis and steatohepatitis

Porteiro, Begoña, Fondevila, Marcos F., Buque, Xabier, Gonzalez-Rellan, Maria J., Fernandez, Uxia, Mora, Alfonso, Beiroa, Daniel, Senra, Ana, Gallego, Rosalia, Fernø, Johan, López, Miguel, Sabio, Guadalupe, Dieguez, Carlos, Aspichueta, Patricia, Nogueiras, Rubén · 2018 · Molecular Metabolism

Abstract

OBJECTIVE: Recent reports have implicated the p53 tumor suppressor in the regulation of lipid metabolism. We hypothesized that the pharmacological activation of p53 with low-dose doxorubicin, which is widely used to treat several types of cancer, may have beneficial effects on nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH). METHODS: We used long-term pharmacological activation of p53 by i.p. or oral administration of low-dose doxorubicin in different animal models of NAFLD (high fat diet containing 45% and 60% kcal fat) and NASH (methionine- and choline-deficient diet and choline deficiency combined with high fat diet). We also administered doxorubicin in mice lacking p53 in the liver and in two human hepatic cells lines (HepG2 and THLE2). RESULTS: The attenuation of liver damage was accompanied by the stimulation of fatty acid oxidation and decrease of lipogenesis, inflammation, and ER stress. The effects of doxorubicin were abrogated in mice with liver-specific ablation of p53. Finally, the effects of doxorubicin on lipid metabolism found in animal models were also present in two human hepatic cells lines, in which the drug stimulated fatty acid oxidation and inhibited de novo lipogenesis at doses that did not cause changes in apoptosis or cell viability. CONCLUSION: These data provide new evidence for targeting p53 as a strategy to treat liver disease.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.molmet.2017.12.005

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 27

  1. Efeyan, 2007, p53: guardian of the genome and policeman of the oncogenes, Cell Cycle, 6, 1006, 10.4161/cc.6.9.4211 · DOI · Paper page
  2. Vousden, 2007, p53 in health and disease, Nature Reviews Molecular Cell Biology, 8, 275, 10.1038/nrm2147 · DOI · Paper page
  3. Goldstein, 2012, Regulation of lipid metabolism by p53-fighting two villains with one sword, Trends in Endocrinology and Metabolism, 23, 567, 10.1016/j.tem.2012.06.007 · DOI
  4. Prokesch, 2017, Liver p53 is stabilized upon starvation and required for amino acid catabolism and gluconeogenesis, The FASEB Journal, 31, 732, 10.1096/fj.201600845R · DOI
  5. Porteiro, 2017, Hepatic p63 regulates steatosis via IKKbeta/ER stress, Nature Communications, 8, 15111, 10.1038/ncomms15111 · DOI
  6. Berkers, 2013, Metabolic regulation by p53 family members, Cell Metabolism, 18, 617, 10.1016/j.cmet.2013.06.019 · DOI · Paper page
  7. Aas, 1996, Specific P53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients, Nature Medicine, 2, 811, 10.1038/nm0796-811 · DOI · Paper page
  8. Al-Massadi, 2016, Pharmacological and genetic manipulation of p53 in brown fat at adult but not embryonic stages regulates thermogenesis and body weight in male mice, Endocrinology, 157, 2735, 10.1210/en.2016-1209 · DOI
  9. Choi, 2011, Effects of quercetin on the bioavailability of doxorubicin in rats: role of CYP3A4 and P-gp inhibition by quercetin, Archives of Pharmacal Research, 34, 607, 10.1007/s12272-011-0411-x · DOI · Paper page
  10. González-Terán, 2016, p38gamma and p38delta reprogram liver metabolism by modulating neutrophil infiltration, The EMBO Journal, 35, 536, 10.15252/embj.201591857 · DOI
  11. Imbernon, 2016, Hypothalamic kappa opioid receptor mediates both diet-induced and melanin concentrating hormone-induced liver damage through inflammation and endoplasmic reticulum stress, Hepatology, 64, 1086, 10.1002/hep.28716 · DOI
  12. Wang, 2004, Doxorubicin induces apoptosis in normal and tumor cells via distinctly different mechanisms. intermediacy of H(2)O(2)- and p53-dependent pathways, Journal of Biological Chemistry, 279, 25535, 10.1074/jbc.M400944200 · DOI · Paper page
  13. Warburg, 1927, The metabolism of tumors in the body, The Journal of General Physiology, 8, 519, 10.1085/jgp.8.6.519 · DOI · Paper page
  14. Santos, 2012, Lipid metabolism in cancer, FEBS Journal, 279, 2610, 10.1111/j.1742-4658.2012.08644.x · DOI · Paper page
  15. Assaily, 2011, ROS-mediated p53 induction of Lpin1 regulates fatty acid oxidation in response to nutritional stress, Molecules and Cells, 44, 491
  16. Goldstein, 2012, p53, a novel regulator of lipid metabolism pathways, Journal of Hepatology, 56, 656, 10.1016/j.jhep.2011.08.022 · DOI
  17. Liu, 2014, Ribosomal protein-Mdm2-p53 pathway coordinates nutrient stress with lipid metabolism by regulating MCD and promoting fatty acid oxidation, Proc Natl Acad Sci U S A, 111, E2414, 10.1073/pnas.1315605111 · DOI · Paper page
  18. Jiang, 2011, p53 regulates biosynthesis through direct inactivation of glucose-6-phosphate dehydrogenase, Nature Cell Biology, 13, 310, 10.1038/ncb2172 · DOI · Paper page
  19. Yahagi, 2003, p53 Activation in adipocytes of obese mice, Journal of Biological Chemistry, 278, 25395, 10.1074/jbc.M302364200 · DOI · Paper page
  20. Derdak, 2013, Inhibition of p53 attenuates steatosis and liver injury in a mouse model of non-alcoholic fatty liver disease, Journal of Hepatology, 58, 785, 10.1016/j.jhep.2012.11.042 · DOI · Paper page
  21. Yahagi, 2004, p53 involvement in the pathogenesis of fatty liver disease, Journal of Biological Chemistry, 279, 20571, 10.1074/jbc.M400884200 · DOI
  22. Farrell, 2009, Apoptosis in experimental NASH is associated with p53 activation and TRAIL receptor expression, Journal of Gastroenterology and Hepatology, 24, 443, 10.1111/j.1440-1746.2009.05785.x · DOI · Paper page
  23. Tomita, 2012, p53/p66Shc-mediated signaling contributes to the progression of non-alcoholic steatohepatitis in humans and mice, Journal of Hepatology, 57, 837, 10.1016/j.jhep.2012.05.013 · DOI · Paper page
  24. Kanno, 2015, Pifithrin-alpha has a p53-independent cytoprotective effect on docosahexaenoic acid-induced cytotoxicity in human hepatocellular carcinoma HepG2 cells, Toxicology Letters, 232, 393, 10.1016/j.toxlet.2014.11.016 · DOI
  25. Sohn, 2009, Pifithrin-alpha protects against DNA damage-induced apoptosis downstream of mitochondria independent of p53, Cell Death & Differentiation, 16, 869, 10.1038/cdd.2009.17 · DOI
  26. Chatterjee, 2010, Doxorubicin cardiomyopathy, Cardiology, 115, 155, 10.1159/000265166 · DOI · Paper page
  27. Babuin, 2005, Troponin: the biomarker of choice for the detection of cardiac injury, CMAJ, 173, 1191, 10.1503/cmaj/051291 · doi:10.1503/cmaj/051291 · Paper page

Cited by

See all 35

Metadata

Authors
Porteiro, B., Fondevila, M. F., Buque, X., Gonzalez-Rellan, M. J., Fernandez, U., Mora, A., Beiroa, D., Senra, A., Gallego, R., Fernø, J., López, M., Sabio, G., Dieguez, C., Aspichueta, P., & Nogueiras, R.
Venue
Molecular Metabolism
Publisher
Elsevier BV
Published
2018-02
Volume
8
Pages
132-143
ISSN
2212-8778
Cited by
35
References
1
Language
en
Licence
Funders
  • Ministerio de Economia y Competitividad (CD: BFU2014-55871, RN: BFU2015-70664-R, GS: SAF2016-79126-R, ML: SAF2015-71026-R, PA: SAF2015-64352-R)
  • Xunta de Galicia (ML: 2015-CP079, RN: 2015-CP080, PIE13/00024)
  • European Community's Seventh Framework Programme (RN: ERC StG-281408, GS: ERC StG-260464)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.